Good News for PharmD Graduates in India : Guess what??

Dear Readers, Thank you for blogging with us..!!!

I'm glad to share this great news with you, upon consistent efforts of the Association for Doctor of Pharmacy (ADP), PharmD Doctor's Welfare Association (PWDA) and all other PharmD associations, since years in India, we have moved way forward in achieving a great milestone in the career path.

Introduction: In recent times, governments around the world have acknowledged the significance of healthcare professionals and the evolving nature of the pharmaceutical industry. As a testament to their commitment to enhancing public health, many governments have taken a commendable step by including Doctor of Pharmacy (PharmD) as an eligibility criterion for various government positions. This progressive decision not only recognizes the unique expertise possessed by PharmD graduates but also ensures the provision of quality healthcare services to the citizens. In this blog, we will delve into the reasons why this move is worthy of appreciation. 

You might have aware that Central Research Institutes/Organizations like the Indian Council of Medical Research (ICMR), Department of Health Research (DHR), Ministry of Health and Family Welfare (MoHFW), Government of India (GoI); Indian Institute of Chemical Technology (IICT), Council of Scientific and Industrial Research (CSIR); Center for Cellular and Molecular Biology (CCMB); Department of Science and Technology (DST); Department of Biotechnology (DBT) etc., and autonomous grant-in-aid institutions like Tata Memorial Centre (TMC), Department of Atomic Energy (DAE), Government of India (GoI) have offered several temporary scientific positions and fellowships for PharmD graduates considering our clinical and scientific skills. I personally was shortlisted for more than 5 Scientific positions (Scientist-B, Scientist-C, Scientist -D, Scientific Consultant, Associate Consultant) etc., in such research organizations. 

Enhancing Healthcare Delivery: The inclusion of PharmD as an eligibility criterion for research and scientific positions demonstrates a proactive approach to improving healthcare delivery. Pharmacists play a crucial role in healthcare teams, acting as medication experts and providing valuable insights into drug therapy. With their specialized training in pharmaceutical sciences, pharmacokinetics, and therapeutics, PharmD graduates possess a deep understanding of drug-related issues and can effectively contribute to medication safety initiatives. By including PharmD graduates in such government positions, their extensive knowledge and skills, enhance the quality of healthcare services, help minimize adverse drug reactions, prevent medication errors, and promote optimal drug utilization, ultimately safeguarding the well-being of the public. The ability of pharmacists to analyze complex medication regimens, manage drug interactions, and offer patient counseling contributes significantly to improving patient outcomes.

Healthcare Policy Development: Government positions often involve policy-making and strategic planning for healthcare systems. Including PharmD graduates in these roles brings a unique perspective to the table. PharmD graduates are trained not only in clinical pharmacy but also in areas such as pharmacoeconomics, health outcomes research, and health policy. Their comprehensive understanding of the pharmaceutical industry allows them to contribute to evidence-based decision-making, drug pricing policies, and healthcare cost containment strategies. The inclusion of PharmD as an eligibility criterion thus enriches the pool of professionals involved in shaping healthcare policies, leading to more informed and effective strategies.

News for today: Indian Council of Medical Research (ICMR) has released a memorandum amending Rule No. 14 and Schedule III of the ICMR, HSRC rules, 2007 communicated by DHR to inlude PharmD as eligibility criteria for various scientific positions along with other graduate and post-graduate qualifications. 

• Scientist - B with Pay level 10 (Rs. 56100-177500) Pre-revised GP: Rs. 5400/-
• Scientist - C with Pay level 11 (Rs. 67700-208700) Pre-revised GP: Rs. 6600/-
• Scientist - D with Pay level 12 (Rs. 78800-209200) Pre-revised GP: Rs. 7600/-
• Scientist - E with Pay level 13 (Rs. 123100-215900) Pre-revised GP: Rs. 8700/-
• Scientist - F with Pay level 13A (Rs. 131100-216600) Pre-revised GP: Rs. 8900/-
• Scientist - G with Pay level 14 (Rs. 144200-218200) Pre-revised GP: Rs. 10000/-

The complete document can be accessed through this weblink: HSRC amendment rules - PharmD

Health Technology Assessment in India (HTAIn) and DHR ICMR Advanced Molecular Oncology Diagnostic Services (DIAMOnDS), Department of Health Research (DHR), Ministry of Health and Family Welfare (MoHFW). Government of India (GoI) has identified the following  institutes as Technical Partners of HTAIn, so far, with a physical target of 125 scientific projects.

1. All India Institute of Medical Sciences (AIIMS), New Delhi.
2. National Institute of Medical Statistics (NIMS), New Delhi
3. National Health Systems Resource Centre (NHSRC), New Delhi
4. Public Health Foundation of India (PHFI), New Delhi
5. Institute of Economic Growth (IEG), New Delhi
6. Indian Institute of Health Management Research (IIHMR), Jaipur
7. Indian Institute of Technology (IIT), Mumbai
8. National AIDS Research Institute (NARI), Pune
9. Indian Institute of Public Health (IIPH), Bhubaneswar
10. Indian Institute of Technology (IIT), Chennai

PharmD graduates were recognised as eligible personnel for the following scientific and technical positions in these projects:

1. Scientist D (Non - Medical) - Rs. 78,000/- per month + HRA
2. Senior Project Officer/ Senior Research Officer - Rs. 78,000/- per month + HRA
3. Research Officer - depends on project
4. Research Associate - depends on project
5. Field Supervisor - depends on project
6. Field Investigator/ Field Officer - Rs. 30,000 - 32,000/- + HRA

The complete document can be accessed through this weblink: HTAIn ICMR guidelines 2021

Career Opportunities for PharmD Graduates: By recognizing PharmD as an eligibility criterion for scientific positions, governments open up a broader range of career opportunities for PharmD graduates. This move encourages more students to pursue the PharmD program, attracting talented individuals to the pharmacy profession. The availability of government positions creates a positive outlook for aspiring pharmacists and strengthens the profession by acknowledging its significance in public health.

Conclusion: The inclusion of PharmD as an eligibility criterion for government positions is a commendable decision that signifies it's commitment to improving public health. By recognizing the expertise of PharmD graduates and providing them with opportunities to contribute to healthcare policy, medication safety, and interprofessional collaboration, governments pave the way for a more robust and effective healthcare system. This step not only benefits patients but also fosters professional growth, scientific evidence and enhances the role of pharmacists in society. It is imperative to appreciate and support such progressive initiatives that acknowledge the evolving nature of healthcare and the indispensable role of PharmD professionals.

Happy Blogging...!!!

Clinical Pharmacy In India: Insights in an International Magazine

Dear Readers, Thank you for blogging with us. 

I'm glad to share my interview published in an International Magazine "Leckarnicke Listy" in March 2018. 

Thank you #Dr. Peter Krajcovic, PhD for the interview.

Disclaimer: This interview was originally conducted in a foreign language during my visit to a few European countries and it is further translated to the English version, hence English grammatical errors and vocabulary can be exempted. 

How to Use Turnitin : 10 Easy Steps

Turnitin is considered as one of the best online resource for detecting plagiarism. It gives a detailed note on similarity index and the sources utilized for the content plagiarised. Here is a detailed note on How to use Turnitin in 10 Easy steps. 

Dr. Deepak Kumar Bandari, PharmD : Short Profile

Thank you for visiting my blog...!!!

Here you can check out my short profile 

Dr. Deepak Kumar Bandari, PharmD, (PhD) (Europe)

Research Scientist, ICMR-NICPR, Noida.

Current Position: National

1) Project Research Scientist - Indian Council of Medical Research (ICMR) - National Institute of Cancer Prevention and Research (NICPR), Noida and Delhi. 

Project: AccEEND TB, India.

2) Board of Studies Member - Master’s in Clinical Research and Experimental Medicine, School of Allied and Health Sciences, Malla Reddy University, Hyderabad.

3) Book reviewer - BSP Publications, Pharma Med Press and Kakatiya Publications.

Current Position: International
PhD Researcher and Early Stage Researcher participant
Project: FIP 7 programme of EuroAgeism H2020 project, involving 13 European and Non-European countries.

Early-Stage Researcher (ESR) Participant, Euro Ageism H2020, Faculty of Pharmacy in Hradec Králové, Charles University, Europe.

Thesis: Polypharmacy and comparison of differences in potentially inappropriate prescribing in India, Ethiopia, and European countries.
Projects and Grants handled: 

• Project: FIP 7 programme of EuroAgeism H2020 project, involving 13 European and Non-European countries.

Grant: European Commission, FIP7 program Euro Ageism H2020-764632-MSCA-ITN supported by the scientific group “Ageing and Changes in the Therapeutic Values of Drugs in the Aged”, Charles University, Progress Programme Q42, SVV program 260 417.
Total Finance - 232 422,48 EU (Detailed budget - not disclosed)
EU Consortium: Israel, Czech Republic (CZ), UK, Poland, Netherlands, Sweden, Finland, Belgium.
Participating countries: Czech Republic, Serbia, Croatia, Bulgaria, Estonia, Turkey, Spain, Ireland, Belgium, India, Ethiopia.
Collaborating Institutions: Alliance Health and Social Care Alliance Scotland (AL), EMDA – The Alzheimer’s Association Israel (AAI), European Centre for Social Welfare Policy and Research (Euro Centre), National University of Ireland Galway (NUIG), United Nations Economic Commission for Europe (UNECE) and World Health Organization (WHO).

• Project No. START/MED/093

Thesis: Rational geriatric pharmacotherapy, medication errors and clinical pharmacy services in long-term care.
Total Finance - 2,299,968 CZK (Personal cost-1,353,600; Mentor remuneration-40,000; Travel costs-361,000; Training costs- 120,000; Costs of non-investment equipment, materials etc. - 80,000; Overhead costs - 345,368)
Grant: Charles University, Research Unit “Ageing, Polypharmacy and Changes in the Therapeutic Value of Drugs in the AgeD”, United Nations Economic Commission for Europe and World Health Organization, University of Zagreb, Croatia, University of Belgrade.

Previous Positions: National

1)Project Technical Support - III (Field Investigator) - Indian Council of Medical Research (ICMR) - National Institute of Nutrition (NIN), Hyderabad, India. 

Project: Strengthening the Monitoring of Tuberculosis Elimination in India - District Level Sentenial Survey (DLSS), India.

2) Associate Consultant (Epidemiology and Outcomes Research) - Bridge Medical Consulting Pvt. Ltd, New Delhi. 

3) Team Leader - Indian Council of Medical Research (ICMR) – National Institute of Nutrition (NIN), Hyderabad, India.

Project: National Sero-surveillance to monitor the trend of SARS-CoV-2 infection transmission in India.

4) Investigator (Field) - Indian Council of Medical Research (ICMR) – National Institute for Research in Tuberculosis (NIRT), Chennai, India.

Project: National survey for the state-wise prevalence of microbiologically confirmed pulmonary tuberculosis in India.

5) Assistant Professor and Clinical Preceptor: Vaagdevi Institute of Pharmaceutical Sciences, Warangal, India. 

No. of Research Publications: 18
Cumulative Impact Factor: 153
Number of Citations: 3000+

h-index: 14; i-10 index: 15 

Awarded grants: Total 7 (International: 6, National: 1)
Achievements: Total 9 (International: 5, National: 4)
My Interviews in Magazines and Newsletters: 3 (International: 2, National: 1)

Scientific presentations: (International: 11, National: 8)
Book reviews: 9 (International: 2, National: 7)
Guest Lectures: Total 3 (International: 1, National: 2)
Editorial member and reviewer: 8
Certification courses: Total 10 (2 - Stanford University, 8 - National and International Organizations)
Countries affiliated: USA, Italy, Poland, Slovak Republic, The Czech Republic, Germany, Hong Kong and 10 other European countries.

International collaborative research: Early Stage Researcher participant in the FIP 7 programme of EuroAgeism H2020 project under Marie-Curie Innovative Network and EU COST Action IS1402 network aimed at describing main prescribing problems in rational geriatric pharmacotherapy in 13 European and Non- European countries (including India and Ethiopia). 

Collaborating Institutions: Alliance: Health and Social Care Alliance Scotland (AL), EMDA – The Alzheimer’s Association Israel (AAI), European Centre for Social Welfare Policy and Research (EuroCentre), National University of Ireland Galway (NUIG), United Nations Economic Commission for Europe (UNECE) and World Health Organization (WHO).

Remarkable Achievements:

1. Award and Position: Early Stage Researcher (ESR) participant in the network of FIP7 EuroAgeism H2020 – ITN project, European Commission.
2. Reviewer: Acknowledged in Davidson’s Principles and Practice of Medicine textbook, 23rd Edition, 2018; Elsevier publishers ISBN: 9780702070280.
3. Personal interview: “I expect the 8-star Pharmacist Concept of World Health Organization will come true in India in the Future” published in an International Magazine “Lekarnicke Listy”, March 2018, Bratislava, Slovak Republic.
4. Best reviewer award: Textbook of Hutchison’s Clinical Methods 23rd International Edition by Michael Glynn &William Drake. Saunders Publishers, UK ISBN: 978-0-7020-4091
5. ERASMUS+ Student Mobility: Internship in various European countries.

A few other Achievements:

1. Award and Interview: Winner of “Ideathon” First Nobel Prize Series in India, Department of Biotechnology, India. Interview entitled “Pharmacist Nobel Prize Series: Science Impacts Lives – The Pride of India”, Indian Pharmaceutical Association – Community Pharmacy Division (IPA - CPD) e-Times 6 (2), March – April 2017.

2. Story of Success (2017): Published by Elsevier, as a part of the budding Medicos National contest.

3. Elsevier Student Ambassador (ESA) and Mentor’ for South Asia from July 2014 to June 2016.

4. Felicitation and award: Special Faculty Achievement Award at Viswambhara Educational Society Silver Jubilee Celebrations, March 2018, Warangal, India.

5. Award: Pharmacy Practice contribution award on World Pharmacist’s Day, 25th September 2017 for the successful delivery of an invited lecture on the Prescriptive role of Clinical Pharmacist in Ambulatory Care at Deccan School of Pharmacy, Hyderabad, India.

Acknowledgement: 

• I thank Prof. Daniela Fialova, PharmD, PhD, BCCP; Chair of the Horizon 2020 EuroAgeism FIP7 program; Head of the University Centre of Clinical Pharmacy, Faculty of Pharmacy, Charles University; Department of Social and Clinical Pharmacy, Faculty of Pharmacy, Charles University, Department of Geriatrics and Gerontology,1st Faculty of Medicine, Charles University, Czech Republic.
• Dr Akshaya Srikanth Bhagavathula, PharmD, PhD; Associate Professor of Epidemiology, Department of Public Health, North Dakota State University, United States of America. 
• Prof. Yamsani Madhusudan Rao, M.Pharm, PhD; Director, Vaagdevi group of Pharmacy Colleges, Warangal, India for their valuable guidance and support throughout my career.

 

Research Opportunity in U.S.A: PharmD II to V year Students

As per the information from official sources upon our enquiry it is clear that the students of PharmD II year to V year can apply. 

For more details refer : Official website

 Public Health Research Initiative (PHRI) Research Grant: 2016-17

Dear Readers..!!! Thanks for visiting my blog...!!!

Public Health Research Initiative (PHRI)

Public Health foundation of India (PHFI) in collaboration with Science and Engineering Research Board (SERB, A Statutory Body under Department of Science and Technology (DST)) aims to set up anextramural fund to provide the Indian researchers focused on public health from institutions of repute, as per an established process. PHRI will enable young Indian researchers to carry out clearly defined research project at a place of their choice up to a period of 36 months.

Project Duration and Cost

These grants will be awarded for research studies of public health importance in India. The estimated amount of the available research grant is limited to 30 Lakh INR per Research Grant. The total duration of the grant will not exceed more than THREE years.

Eligibility Criteria

The applicant must possess a Post-Graduate degree from an accredited institution in any domain related to public health, including medical and non-medical sciences, nutrition, physiotherapy, dentistry, pharmacy, nursing, social sciences, law and humanities. It would be desirable if the applicant has a doctoral degree. (Applications related to Biomedical, Biophysics and biochemistry are excluded from PHRI Research Grants)

Age Criteria

The applicant must be 40 years or less at the time of applying for the PHRI Research Grant, age relaxation of 5 years is applicable for female or if applicant belong to SC/ST/OBC then

Application procedure:

Candidates are requested to apply online

a) Online application formats with detailed guidelines are available at the website www.phfi.org Guidelines for Submitting a proposal

This should include the following

1. Title of the study
2. Overall goal
3. Broad Objective
4. Specific objectives
5. Methodology
6. Analysis plan
7. Expected outcome
8. Timeline
9. Implications for future research
10. References
11. Dissemination and publication plan
12. Itemized budget along with justification for each item
13. Curriculum vitae of investigator listed in the grant application

Word limit: Not more than 3000 words (excluding references, Dissemination plan, Itemized budget and Curriculum Vitae) Font Style: Times New Roman Font Size: 12 with Line Spacing 1.5

Kindly note following should be mentioned while sending the grant application:

Area of work:

Area proposed by candidate should be clearly defined research area in any aspect of Public Health like Public Health Nutrition, Non Communicable Diseases, Infectious Diseases and Public Health Policy etc.

Place of work:

A project site in India, depending on the demand of the research study.

The PHFI reserves the right to reject the Research Grant application in case candidate DOES NOT FULFILL minimum qualification or supplies any false information.

Public Health Research Initiative (PHRI) Research Grant: 2016

Online submission will close by 30 June 2016 after 5:00 PM.

Apply Here

Happy Blogging...!!!

Good News for Pharm.D graduates : Tata Memorial Centre Fellowships

Dear Readers..!!! Thanks for visiting my blog...!!!

View Notification Here

Apply Here

Happy Blogging...!!!

Regards,

Deepak Kumar Bandari,

Pharm.D Intern,

Vaagdevi College of Pharmacy - India

Elsevier Student Ambassador - South Asia

New Study Reveals Tamoxifen Reduces Breast Cancer Rates by Nearly a Third for 20 Years

Dear Readers..!!! Thanks for visiting my blog...!!!

A new study has shown that the preventive effect of the breast cancer drug, tamoxifen, remains virtually constant for at least 20 years, with breast cancer rates reduced by around 30 percent. Median 16-year follow-up results from the IBIS-I (International Breast Cancer Intervention-I) trial show a 29% lower risk for developing breast cancer among women who had been randomly assigned to five years of tamoxifen than for women assigned to five years of placebo.

“Tamoxifen is a well-established and effective treatment for certain breast cancers, but we now have evidence of its very long-term preventive benefits…" said Professor Jack Cuzick, IBIS-I lead author and Head of the Centre for Cancer Prevention at Queen Mary University of London. Professor Cuzick underscored the “strong and unabated” 20-year preventive effect of breast cancer resulting in a reduction in breast cancer rates of around a third. “We hope these results will stimulate more women, particularly younger women, to consider treatment options for breast cancer prevention if they have a family history of the disease or other major risk factors.”

The IBIS-I results were presented on December 11, 2014 at the San Antonio Breast Cancer Symposium (SABCS 2014) in Texas and published simultaneously in The Lancet Oncology. SABCS is an international scientific symposium for interaction and exchange among basic scientists and clinicians in breast cancer.

It was organized by the Cancer Therapy & Research Center at UT Health Science Center San Antonio, the American Association for Cancer Research, and Baylor College of Medicine. The IBIS-I study, which began recruitment in 1992, enrolled 7,154 pre- and post-menopausal women aged from 35 to 70 years at high risk for breast cancer primarily because of a family history. They were randomly assigned to receive either tamoxifen 20 mg daily for five years (3,579) or placebo (3,575).

Hormone replacement therapy was allowed during the trial and was used by 49.5% in the placebo group, and approximately 35% of women in each group had had a hysterectomy. The median age at enrollment was 50.8 years in each group. At a median of 16 years of follow-up (longest follow-up 22 years), there were 601 breast cancers reported, 251 (7.0%) occurring in women who took tamoxifen, and 351 (9.8%) in women who took placebo.

In subanalysis, the most pronounced reductions in risk were seen for invasive estrogen-receptor-positive (ER+) breast cancer and ductal carcinoma in situ. However, tamoxifen did not significantly reduce the risk for invasive estrogen-receptor-negative (ER-) breast cancer. The extended analysis of the IBIS-I trial was announced a year after the first results of the IBIS-II trial were released, which found taking the breast cancer drug anastrozole (an aromatase inhibitor) for five years reduced the chances of post-menopausal, high-risk women developing the disease by 53% compared with women who took a placebo. Professor Cuzick concludes: “For most post-menopausal women, an aromatase inhibitor such as anastrozole should be the drug of choice, as it is more effective than tamoxifen and has fewer side effects. However… “…for most premenopausal, high-risk women, tamoxifen remains the only drug of choice for breast cancer prevention and it is a good one, as shown by this new evidence.”

Most Filipino patients cannot afford cost of breast cancer screening, treatment

In the Philippines, which has the highest rate of breast cancer in Asia, low awareness may not be the main reason why the majority of breast cancer cases are not diagnosed early. “Most Filipino patients cannot afford the cost of diagnostic tests and treatments for breast cancer,” states the 2010 Philippine Cancer Facts and Estimates, a document published by the Department of Health and Philippine Cancer Society.

Experts recommend that women, starting at the age of 30, perform monthly self breast examination (SBE) and undergo an annual clinical breast examination (CBE) performed by a healthcare professional. Annual mammogram is recommended for women beginning age 40. According to the 2010 Philippine Cancer Facts and Estimates, national breast cancer awareness campaigns which do not include the provision of diagnosis and treatment are outdated and ineffective. It recommended that each province, city, municipality and barangay should establish and implement its own program for breast cancer diagnosis and treatment.

For such a program to succeed and be sustainable, local government officials, insurance providers, NGOs and civic-minded individuals and organizations, health workers and medical specialty societies must work together in providing access to breast cancer screening and treatment.

References:

1. http://www.medscape.com/viewarticle/836478

2. http://www.qmul.ac.uk/media/news/items/smd/144949.html

3.http://www.mayoclinic.org/diseases-conditions/breast cancer/basics/symptoms/con-20029275

4. http://www.philhealth.gov.ph/news/2012/z_benefits.html

For more Updates, follow us on Facebook. 

Happy Blogging...!!!

Regards,

Deepak Kumar Bandari,

Pharm.D Intern,

Vaagdevi College of Pharmacy - India

Elsevier Student Ambassador - South Asia

Top High Quality Research Universities : 2015

Dear Readers..!!! Thanks for visiting my blog...!!!

The US is the world's largest contributor to high-quality scientific research papers, followed by China and Germany, according to the Nature Index 2016 Tables. Of the top ten countries in the Nature Index, only China has shown double digit compound annual growth between 2012 and 2015 with some of its universities growing their contribution to the index as fast as 25% annually. US contributions have declined 2.8% in the same period from a very high base.

The Nature Index Tables, which show Nature Index calendar year outputs for the last four years, are released together today for the first time. The Nature Index is built on a country or institution's contribution to about 60,000 high-quality papers each year, and counts both the total number of papers and the relative contribution to each paper. (See 'About the Nature Index' for full definitions of measures.)

Harvard University, US, has the highest 2015 contribution of any university in the world. Stanford University (second), Massachusetts Institute of Technology (fourth), University of California, Berkeley (seventh), University of California, San Diego (ninth) and University of Michigan (tenth) — all from the US — occupy top ten positions. The University of Tokyo, Japan, is placed third, the Universities of Oxford and Cambridge, UK, are fifth and sixth, respectively, and ETH Zurich, Switzerland, is placed eighth.

Reference : http://www.nature.com/press_releases/nature-index-2016.html

For more Updates, follow us on Facebook. 

Happy Blogging...!!!

Regards,

Deepak Kumar Bandari,

Pharm.D Intern,

Vaagdevi College of Pharmacy - India

Elsevier Student Ambassador - South Asia

Vacancy in Drug resistant Breast Cancer project at NIN

Dear Readers..!!! Thanks for visiting my blog...!!!

NIN has attained global recognition for its pioneering studies on various aspects of nutrition research, with special reference to protein energy malnutrition (PEM). Institute’s activities are broad-based, encompassing the whole area of food and nutrition. The Institute has achieved close integration in its research activities between the laboratory, the clinic and the community.

Name of the post/ position: Junior Research Fellow

Eligible candidates are invited to apply for the following post/ position on the ad hoc research project entitled: "Drug resistant Breast Cancer Cells to understand Cancer Stem Cells metabolism and therapy" funded by DBT at this Institute.

Applications will be received from the individuals on 5th January, 2016 between 9:30 A.M. and 10:30 A.M. at Conference Hall, NIN, Tarnaka, Hyderabad. Late applications will not be entertained after 10:30 A M under any circumstances. The Candidates may download Application form from NIN website.

The essential qualification, experience, consolidated Pay and service tenure are as under:

Essential Qualifications: Post Graduate Degree in Basic Science with NET qualification or Graduate Degree in Professional Course with NET qualification or Post Graduate Degree in Pharmacy from recognized University.

Desirable: Masters in Pharmacy or Bachelor in Pharmacy with GATE or GPAT exam qualifying score or M.Sc. in Biochemistry/ Biotechnology/ Life Science with NET qualifying score.

Age: Below 30 years. Relaxation of age is admissible as per G O.I. Rules.

Consolidated Stipend/ Emoluments: Rs. 12,000.00 + 30% HRA per month fixed without any other allowances.

Tenure: Initially for one year and extendable based on performance and funds position.

Date & Time of Written Test/ Interview: 5th January, 2016 from 9:30 A.M. onwards.

The shortlisted candidates should bring all original certificates of educational qualification (from SSC onwards), experience, SC/ST/OBC Community Certificate/ PH Certificates along with a pass port size photograph and set of Photo copies duly attested for attending the Written Test/ Interview. The persons belonging to Other Backward Category should bring the latest O.B.C. (Non-creamy layer) Certificate issued by the respective Tahsildar/ MRO specifically issued for the purpose of applying for Central Government Post. No TA/ DA will be paid for attending the Written Test/ Interview.

GENERAL CONDITIONS: The conditions of employment will be the same as that for the project staff on contract basis. The candidates have no right to claim for any regular employment at this Institute. The Director in-charge & Appointing Authority has the right to accept/ reject any application without assigning any reason/s and no correspondence in this matter will be entertained. Age, experience etc., will be reckoned as on 14 12.2015.

Selection Procedure: Written test/Interview will be conducted to the eligible candidates, if the large numbers of candidates are found to be eligible in the screening. If the lesser number of candidates are found to be eligible in the screening, interview will be conducted only to the eligible candidates for final selection. If written test is conducted, the names of the shortlisted candidates will be displayed on the Notice Board, which is kept in front of the Conference Hall on the same day.

Note: The applications will not be accepted by post/ courier.

For more Updates, follow us on Facebook. 

Happy Blogging...!!!

Regards,

Deepak Kumar Bandari,

Pharm.D Intern,

Vaagdevi College of Pharmacy - India

Elsevier Student Ambassador - South Asia

Call for the IPSF Internship at WHO – Famous Pharmacist Study

Dear Readers..!!! Thanks for visiting my blog...!!!

IPSF is delighted to introduce you to an internship opportunity at the World Health Organization. Through IPSF, the WHO Unit for Health Promotion will recruit one pharmacy student or recent graduate to work at their main headquarters in Geneva. 

Scope: The internship offered is for a position assisting with the Famous Pharmacist Study, which focuses on the role of the pharmacist, based on review of the work of prominent pharmacists. 

Duration: The length of the internships will be from two to three months. Regarding the terms of internship, flexibility is possible, however the earliest start date is preferred.

Program & Candidate Qualifications : Under the supervision of Dr Kwok-Cho Tang, Coordinator of the Health Promotion and Noncommunicable Diseases and Mental Health department, the intern will execute various tasks in the context of the research project. Based on the nature of the project, the ideal candidate should:

• Possess excellent writing skills

• Have experience in qualitative research methods

• Have completed his or her undergraduate pharmacy study

Depending on the intern’s area of interests and skills, alongside with the approval from the WHO supervisor, IPSF additionally offers an opportunity to:

• Contribute to the IPSF Policy/Public Health Committee as a co-opted member

• Partake in the IPSF delegation to the 57th WHO World Health Assembly.

• Attend conferences and represent IPSF at United Nation meetings in Geneva with either permanent or special ground passes to UN buildings.

Eligibility: WHO may accept applicants who meet all of the following conditions as interns:

• Applicants who are fluent in English

• Applicants must not be related to a WHO staff member (e.g., son/daughter, brother/sister or mother/father)

• Applicants cannot have participated previously in a WHO internship program

• Applicants who are not current tobacco users.

Applications invited for SRF and RA : CSIR -2015

Dear Readers..!!! Thanks for visiting my blog...!!!

The Human Resource Development (HRD) Group of Council of Scientific and Industrial Research (CSIR), New Delhi, provides opportunities to bright young men and women in the form of direct Senior Research Fellowships (SRFs) and Research Associateships (RAs) for training in methods of research under the expert guidance of faculty members/scientists working in universities, laboratories and institutes of Government Departments and recognised laboratories of industry in various fields of science and technology.

Preference will be given to the research topics relevant to R&D programmes of CSIR Laboratories, in the new and emerging fields of science and in the areas of importance for development of scientific and technological capability of the country. The Fellowships/ Associateships are tenable in all the universities and deemed universities/IITs/postgraduate colleges/government research establishments including those of CSIR, R&D establishments of recognised public sector, industrial firms and other recognised institutions. Only bonafide Indian citizens are eligible for the award. The award is for fixed tenure and does not imply any assurance or guarantee for subsequent employment by CSIR to the beneficiary. CSIR reserves the right to determine the place in India best suited to provide necessary facilities in the areas of science in which the awardee is to specialize. Selected Fellows and Associates will have to devote their full time to the approved research programmes. Fellows and Associates are not permitted to take up any other remunerative jobs/assignments during their tenure.

A. SENIOR RESEARCH FELLOWSHIPS

ESSENTIAL QUALIFICATIONS:

MSc/BE/B. Tech or equivalent degree with at least 55% marks and one publication in Science Citation Indexed (SCI) Journal and should have completed at least two years of post MSc/BE/B. Tech research experience as on the last date of application, as evidenced from fellowship/ associateship or from date of registration for Ph.D.

OR

MTech/ME or equivalent degree in engineering/technology with at least 60% marks.

OR

BE/B. Tech or equivalent degree with at least 60% marks and two years research experience as on the last date of application.

OR

MBBS/BDS or equivalent with at least 60% marks and one year internship.

OR

BPharm/BVSc/BSc(Ag) or equivalent degree with at least 55% marks and one publication in SCI Journal and should have completed at least three years research experience as on the last date of application, evidenced from fellowship/associateship or from date of registration for Ph.D.

OR

Apply Online on or before 14th December 2015 at http://www.csirhrdg.res.in

WHO Internship programme : Applications are invited

Dear Readers..!!! Thanks for visiting my blog...!!!

The World Health Organization (WHO) as the leader in global public health issues is committed to building future leaders in public health. WHO's Internship Programme offers a wide range of opportunities for students to gain insight in the technical and administrative programmes of WHO.

Unfortunately, WHO internships are not paid and all costs of travel and accommodation are the responsibility of the intern or the sponsoring institution.

Who are we looking for? 

• You are enrolled in a degree programme in a graduate school (second university degree or higher) both at the time of application and during the internship.
• You have completed at least three years of full-time studies at a university or equivalent institution towards the completion of a degree.
• You are at least 20 years old.
• You possess a first degree in a public health, medical or social field related to the technical work of WHO or a degree in a management-related or administrative field.
• Fluent in the working language of the office of assignment.

How can I apply?

To apply, you must submit a completed WHO Personal History Form (PHF) [MS Word 294] along with a duly signed Cover Letter.
The Cover Letter should express your motivation for applying for a WHO Internship (maximum length - three paragraphs), WHO work area of interest and dates of availability.

WHO Personal History Form (PHF)

Applications should be sent to:

Personnel-Recruitment Unit

World Health Organization

Regional Office for South-East Asia

World Health House

Indraprastha Estate

New Delhi-110002, India

Telephone: 011-23370804

Email: perrec@searo.who.int

Conditions of WHO internships : The duration of WHO internships is between a minimum of 6 weeks to a maximum of 12 weeks. Exceptionally, internships may be extended up to 24 weeks to respond to special academic requirements or particular needs of the receiving programme.

• WHO internships are not paid. Travel costs, travel arrangements (including visas), and living accommodations are the responsibility of the intern or their sponsoring institution.
• Persons related to a WHO staff member, i.e., son/daughter, brother/sister are not eligible for an internship.
• WHO Interns must have adequate medical insurance coverage during the entire period of the internships.
• Interns may participate only once in the WHO Internship Programme.
• Interns do not have the status of WHO staff members and shall not represent the Organization in any official capacity.
• WHO Interns are not eligible for appointment to any position within WHO for a period of three months following the end of their internship. Any employment with WHO at that point in time shall be subject to established recruitment and selection procedures.

Detailed policy regarding interns

If you have any questions please do not hesitate to contact us at

perrec@searo.who.int

For more Updates, follow us on Facebook. 

Happy Blogging...!!!

Regards,

Deepak Kumar Bandari,

Pharm.D Intern,

Vaagdevi College of Pharmacy - India

Elsevier Student Ambassador - South Asia